Successful transcatheter aortic valve in valve implantation for degenerated trifecta bioprosthesis in a patient with a coronary anomaly

2021 ◽  
Author(s):  
Akiko Yamagata ◽  
Satoru Domoto ◽  
Kazuki Tanaka ◽  
Yusuke Inagaki ◽  
Hisao Otsuki ◽  
...  
Keyword(s):  
Aortic Valve ◽  
Coronary Anomaly ◽  
Transcatheter Aortic Valve ◽  
Valve In Valve ◽  
Valve Implantation

A valve-in-valve transcatheter aortic valve implantation with commissural alignment using advanced imaging reconstruction: a case report

2020 ◽  
Vol 3 (10) ◽  
pp. 01-05
Author(s):  
Marco Angelillis
Keyword(s):  
Aortic Valve ◽  
Severe Aortic Stenosis ◽  
Coronary Intervention ◽  
Easy Access ◽  
Surgical Aortic Valve Replacement ◽  
Transcatheter Aortic Valve ◽  
Structural Valve Deterioration ◽  
Valve In Valve ◽  
Transcatheter Valve ◽  
Valve Implantation

Transcatheter valve in valve (ViV) implantation actually represents a valid alternative to surgical reinterventions in patients with previous surgical aortic valve replacement (AVR). In patients less than 80 years old, it is crucial to correctly position the new valve leaving a feasible and easy access to coronary ostia, both for future percutaneous coronary intervention (PCI) than for a future possible TAVinTAV procedure. We report a 71 year old man with prior AVR presented with structural valve deterioration (SVD) leading to severe aortic stenosis. In order to guarantee comfortable coronary access we aligned, the commissures of the new percutaneous valve with the ones of the surgical bioprothesis by reconstructing the headframes of the surgical bioprosthesis with computer tomography (CT) and fluoro-CT.

scholarly journals Valve-in-valve transcatheter aortic valve implantation with fracturing of a failed small surgical aortic bioprosthesis: a case report

2020 ◽  
Author(s):  
Matjaz Bunc ◽  
Miha Cercek ◽  
Tomaz Podlesnikar ◽  
Simon Terseglav ◽  
Klemen Steblovnik
Keyword(s):  
Aortic Valve ◽  
Transcatheter Aortic Valve Implantation ◽  
Ex Vivo ◽  
Bioprosthetic Valve ◽  
Heart Team ◽  
Transcatheter Aortic Valve ◽  
Patient Prosthesis Mismatch ◽  
Valve In Valve ◽  
Aortic Valve Implantation ◽  
Valve Implantation

Abstract Background Failure of a small surgical aortic bioprosthesis represents a challenging clinical scenario with valve-in-valve (ViV) transcatheter aortic valve implantation (TAVI) often resulting in patient-prosthesis mismatch. Bioprosthetic valve fracture (BVF) performed as a part of the ViV TAVI has recently emerged as an alternative approach with certain types of surgical bioprostheses. Case summary An 81-year-old woman with a history of three surgical aortic valve procedures presented with heart failure. Aortic bioprosthesis degeneration with severe stenosis and moderate regurgitation was found. The patient was deemed a high-risk surgical candidate and the heart team decided that ViV TAVI was the preferred treatment option. Due to the very small 19 mm stented surgical aortic bioprosthesis Mitroflow 19 mm (Sorin Group, Italy) we decided to perform BVF as a part of ViV TAVI to prevent patient-prosthesis mismatch. Since this was the first BVF procedure in our centre, an ex vivo BVF of the same kind of bioprosthetic valve was performed first. Subsequently, successful BVF with implantation of Evolut R 23 mm (Medtronic, USA) self-expandable transcatheter valve was performed. Excellent haemodynamic result was achieved and no periprocedural complications were present. The patient had an immediate major improvement in clinical status and remains asymptomatic after 6 months. Discussion Bioprosthetic valve fracture together with ViV TAVI is a safe and effective emerging technique for treatment of small surgical aortic bioprosthesis failure. Bioprosthetic valve fracture allows marked oversizing of implanted self-expandable transcatheter aortic valves, leading to excellent haemodynamic and clinical results. An ex vivo BVF can serve as an important preparatory step when introducing the new method.

Valve-in-Valve Implantation Using a Novel Supravalvular Transcatheter Aortic Valve: Proof of Concept

2009 ◽  
Vol 88 (6) ◽  
pp. 1864-1869 ◽  
Author(s):  
Ali N. Azadani ◽  
Nicolas Jaussaud ◽  
Peter B. Matthews ◽  
Liang Ge ◽  
T. Sloane Guy ◽  
...  
Keyword(s):  
Aortic Valve ◽  
Proof Of Concept ◽  
Transcatheter Aortic Valve ◽  
Valve In Valve ◽  
Valve Implantation

scholarly journals Intracardiac Visualization of Transcatheter Aortic Valve and Valve-in-Valve Implantation in an In Vitro Passive Beating Heart

2013 ◽  
Vol 6 (1) ◽  
pp. 92-93 ◽  
Author(s):  
Alberto M. Leopaldi ◽  
Riccardo Vismara ◽  
Guido Gelpi ◽  
Claudia Romagnoni ◽  
Gianfranco B. Fiore ◽  
...  
Keyword(s):  
Aortic Valve ◽  
Beating Heart ◽  
Transcatheter Aortic Valve ◽  
Valve In Valve ◽  
Valve Implantation

scholarly journals Long-term Transcatheter Aortic Valve Durability

2019 ◽  
Vol 14 (2) ◽  
pp. 62-69 ◽  
Author(s):  
Giuliano Costa ◽  
Enrico Criscione ◽  
Denise Todaro ◽  
Corrado Tamburino ◽  
Marco Barbanti
Keyword(s):  
Aortic Valve ◽  
European Association ◽  
Standard Of Care ◽  
Transcatheter Aortic Valve ◽  
Risk Patients ◽  
International Data ◽  
Valve In Valve ◽  
European Society Of Cardiology ◽  
Valve Implantation

Transcatheter aortic valve implantation (TAVI) has become the standard of care for high-risk and inoperable surgical patients and a valid alternative to surgery for low- and intermediate-risk patients with severe, symptomatic aortic stenosis. It is increasingly being used for younger, lower-risk patients, so it is important to ensure the durability for long-term transcatheter aortic valves. The lack of standard definitions of structural valve degeneration (SVD) had made comparison among studies on prosthetic valve durability problematic. The 2017 standardised definitions of SVD by the European Association of Percutaneous Cardiovascular Intervention), the European Society of Cardiology and the European Association for Cardio-Thoracic Surgery, and the 2018 definitions by the Valve In Valve International Data group, has generated an increased uniformity in evaluations. This article examines the potential mechanisms and rates of SVD of transcatheter bioprostheses and the role of redo TAVI as a treatment option.

Sign in / Sign up

Export Citation Format

Share Document